Risankizumab
Skyrizi (risankizumab) is an antibody pharmaceutical. Risankizumab was first approved as Skyrizi on 2019-04-23. It is used to treat psoriasis in the USA. It has been approved in Europe to treat psoriasis. It is known to target interleukin-23 subunit alpha.
| Trade Name | Skyrizi |
|---|---|
| Common Name | Risankizumab |
| Indication | psoriasis |
| Drug Class | Monoclonal antibodies: humanized, interleukins as target |
